Abstract: Introduction: Ischemic stroke accounts for ~87% of all stroke cases (Virani et al., 2020). It is a leading cause of death and long-term disability worldwide, and constitutes a major burden for families and healthcare systems alike. Although medical treatment can help prevent stroke, post-stroke treatment is limited to either pharmacologic (e.g., tissue plasminogen activator - tPA) or mechanical (e.g., thrombectomy) reperfusion. During the past few decades, many neuroprotective and neurorestorative strategies have been tested in hopes of discovering improved treatment options for stroke patients, particularly patients who are not eligible for reperfusion therapy. Sadly, such hopes have not yet been fulfilled, and thus, patients are still in dire need of new stroke therapies as well as increased vigilance for amelioration of risk factors.